Reviva Pharmaceuticals Q3 2026 Earnings Date & Estimates

Reviva Pharmaceuticals (NASDAQ:RVPH) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system, cardiometabolic and inflammatory disorders. The company’s research is based on compounds designed to modulate serotonin and dopamine receptors, which are involved in multiple neurological and psychiatric conditions.

Reviva’s lead product candidate is brilaroxazine, formerly known as RP5063. Brilaroxazine is an investigational, once-daily small molecule being developed primarily for schizophrenia and other potential neuropsychiatric indications. The company has also evaluated its potential applications in conditions involving inflammation and cardiometabolic dysfunction. Brilaroxazine remains an investigational therapy and has not been approved for commercial use.

Reviva Pharmaceuticals was founded to advance drug candidates derived from its proprietary serotonin-dopamine activity platform. The company is headquartered in the United States and conducts development activities through clinical research and collaborations with healthcare and research organizations. Its programs are intended for patients in international markets, although the availability of any product would depend on regulatory approvals in individual jurisdictions.